Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat (BI 685509) for Portal Hypertension in Cirrhosis
NCT05282121Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of avenciguat in Portal Hypertension (PH), sponsored by Boehringer Ingelheim. Started Jun 2022; status: terminated.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT05282121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282121.